The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes-Reference-Cited by-同舟云学术

The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes

Published:2017 Issue:7 Volume:24 Page:735-748
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Shinnakasu Atsushi¹,Yamamoto Kiyoaki¹,Kurano Mihoko¹,Arimura Hiroshi¹,Arimura Aiko¹,Kikuti Akira¹,Hashiguchi Hiroshi¹,Deguchi Takahisa¹,Nishio Yoshihiko¹

Affiliation:

1. Department of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Sciences

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/24/7/24_39446/_pdf

Reference31 articles.

1. 1) Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ, 1998; 316: 823-828

2. 2) Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet, 2008; 371: 117-125

3. 3) Lorenzo C, Hartnett S, Hanley AJ, Rewers MJ, wagenknecht LE, Karter AJ, Haffner SM: Impaired fasting glu cose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study. J Clin Endocrinol Metab, 2013; 98: 1622-1630